Penn Medicine researchers digging through more than 110,000 women’s medical records say they have spotted something striking: overweight and obese patients who used GLP‑1 medications were roughly 30% less likely to be diagnosed with breast cancer. The team argues the signal is strong enough to justify a randomized clinical trial to test whether the drugs, already prescribed for diabetes and weight loss, can actually prevent breast cancer. The finding is still preliminary but is hard to ignore given how fast GLP‑1 use is climbing nationwide.
Study cohort and headline result
The retrospective analysis pulled electronic health records for 111,646 women ages 45 to 80 with a body‑mass index of 25 or greater who underwent breast imaging within the Penn Medicine system; about 15,264 of them had documented GLP‑1 prescriptions. Researchers then compared new breast‑cancer diagnoses in both the full cohort and in a one‑to‑one matched cohort of 30,528 women. They found 35.1% lower odds of breast cancer in the full sample and roughly 30.5% lower odds in the matched analysis. Those findings were published in JCO Oncology Practice.
Adjusted analysis and limits
The association held up even after adjusting for age, race and ethnicity, BMI, breast density and type 2 diabetes, which makes it less likely that the signal is explained entirely by measured differences between users and nonusers. At the same time, the investigators stress that the study is observational. It did not break out results by individual GLP‑1 agent, dose or treatment duration and therefore cannot prove causation. Additional analyses to dig into tumor subtype, timing and other possible confounders are already on the to‑do list, as reported by ScienceDaily.
Trial plans and collaborators
Lead author Dr. Elizabeth McDonald and colleagues are sketching out a multisite randomized trial that would initially enroll more than 100,000 women already participating in a national mammography screening study, and they are working with groups that include the American College of Radiology and the American Society of Clinical Oncology to build it. The American College of Radiology has pointed to the existing TMIST screening cohort as an ideal starting population, but organizers note the effort is not yet fully funded and will require partnerships that span government, industry and foundations. The planning and funding needs have been described by the study team and ACR officials, per American College of Radiology.
Researchers' caution and a striking quote
“If this is reducing cancer risk by 30%, that’s tens of thousands of cases,” said Dr. Elizabeth McDonald, the study’s lead author and a breast radiologist at Penn Medicine, a remark reported by WHYY. The line captures the potential public‑health punch if the signal is real, but outside experts emphasize that observational findings are hypothesis‑generating and need randomized trials to establish causality. The authors say they are moving carefully but steadily to design a trial that can answer whether GLP‑1 exposure truly cuts breast‑cancer incidence.
What patients should know
Clinicians are urging patients not to sprint ahead of the evidence. GLP‑1 medications come with side effects, high costs and unsettled long‑term safety when used purely for prevention, and current data do not support starting these drugs solely to lower cancer risk. GLP‑1 agents such as Ozempic and Wegovy are already widely prescribed for diabetes and weight loss, and research into possible cancer links is expanding, according to Healthline. For now, experts say the usual playbook still applies: maintain a healthy weight, keep up with recommended breast‑cancer screening and talk with a clinician about the risks and benefits of any medication.
For Philadelphia and far beyond, the Penn analysis feeds into a fast‑moving conversation about repurposing metabolic drugs for cancer prevention. The clear next step is a well‑designed randomized trial that can confirm any benefit, sort out who might benefit the most and clarify safety. Penn researchers say they are continuing trial planning and fundraising, per Penn Medicine via EurekAlert.
